TrialNature communications2026

Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trial.

Liying Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.